GeneType Clinicians’ Adoption Growing - Sales up 5-Fold Year on Year


MELBOURNE, Australia, April 16, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to share the company’s latest milestones along with our clinical adoption of the Company’s groundbreaking geneType Risk Assessment Tests routinely across 12 states in the United States and nationally in Australia.

The geneType team has achieved clinical proof of concept in key markets including general practice, oncology, and gynecology with repeat sales in each of these markets.

Increasingly clinicians are realising the importance of genetic screening for disease, particularly in at risk patients. The ability to “know” a patient’s risk provides clinicians with an opportunity to offer a greater standard of care and more closely monitor those at risk. Clinicians embracing and offering geneType to patients have tended to be:

  • Early adopters
  • Comfortable with new technology
  • Focussed on offering patients the best available care; and
  • Comfortable with explaining results to patients.

Clinical adoption of geneType is now in more than 12 US States, Canada and nationally in Australia. Commercial tests received for the 6 months ending March 31, 2024 increased 543%, when compared with the same period last year, demonstrating the company is well on a pathway to profitability. This adoption and clinical utility demonstrate clinicians’ commitment to offering an improved standard of care to patients and willingness to adopt new technology into clinical practice. The ability to identify and predict a patient’s risk of cancer empowers clinicians and patients, providing actionable insights into individuals' threat of developing disease, enabling personalized surveillance resulting in early detection, improved patient outcomes and a potential reduction in healthcare costs.

The geneType test is powered by combining cutting-edge genetic analysis and clinical factors with state-of-the-art AI and machine learning techniques to offer clinicians unparalleled insights into patients' risk of disease.

Rockville Maryland based Dr Carolyn Young, a board-certified Obstetrician and Gynecologist, commented: “There are two common misconceptions in breast cancer risk. Firstly, women think they are at low risk because they have no family history and secondly if they find out they are at high-risk there is nothing they can do about it. In both cases this is incorrect; family history accounts for only about 10-15% of breast cancer risk, the balance, 85-90% is sporadic and non-hereditary. By knowing your risk there are number of things a patient can do to decrease that risk, including changes to lifestyle, increased screening such as breast MRI in conjunction with mammography and finally, risk reducing medications. Using the geneType breast cancer risk assessment test I can help my patients understand these risks and deploy a range of actions to improve outcomes for them.”

The growing rate of patient and clinical adoption and increasing sales can be attributed to several key factors:

  • Patients are increasingly understanding the benefits of genetic screening, its ability to predict certain cancers before symptoms arise, allowing for earlier interventions, personalised medicine, introduction of preventative measures, family planning and potentially better outcomes. Overall genetic testing offers patients peace of mind and empowers them to take better control of their health.
  • Doctors are becoming increasingly aware of clinically backed genetic screening technologies that provide detailed information on patients’ risk of developing cancer and other conditions. Even more importantly, clinicians are becoming increasingly confident with using these technologies and offering them to patients - providing early disease detection, actionable results, and the ability to offer patients personalised and superior care.

GENE is positioning as a leader in the field, through:

  • Comprehensive Support: GENE's dedicated team of experts provides comprehensive support to clinicians, offering training, education, and ongoing assistance to ensure seamless integration of the geneType test into their practice.
  • Evidence-Based Solutions: GENE is committed to delivering evidence-based solutions that have been rigorously validated through extensive research and clinical studies, instilling confidence in clinicians and patients alike.
  • Global Reach: GENE's widespread presence across the USA and Australia ensures that clinicians from diverse geographic regions have access to the geneType test, democratizing personalized healthcare and improving patient outcomes on a global scale. Importantly GENE is well advanced in launching geneType in several other important geographical markets.

“Our success in expanding clinician adoption and growth in sales reflects the growing recognition of the transformative potential of personalized medicine,” remarked Simon Morriss, CEO of GENE. “By harnessing the power of geneType, we are empowering clinicians to deliver targeted interventions that improve patient outcomes and drive the future of healthcare forward.”

With the geneType test gaining momentum among across the USA and Australia, GENE remains steadfast in its mission to revolutionize healthcare through its constant pursuit in excellence in innovation.

For more information about GENE and the GeneType test, visit

Authorised for release by the Board of Directors.


Simon Morriss
Chief Executive Officer

About Genetic Technologies Limited

Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness, and serious disease through its geneType and EasyDNA brands. GENE offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products. For more information, please visit

Forward Looking Statements

This announcement may contain forward-looking statements about the Company's expectations, beliefs or intentions regarding, among other things, statements regarding the expected use of proceeds. In addition, from time to time, the Company or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as "believe," "expect," "intend," "plan," "may," "should" or "anticipate" or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by the Company with the U.S. Securities and Exchange Commission, press releases or oral statements made by or with the approval of one of the Company's authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. As forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause the Company's actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause the Company's actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements as detailed in the Company's filings with the Securities and Exchange Commission and in its periodic filings with the ASX in Australia and the risks and risk factors included therein. In addition, the Company operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond its control. The Company does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Globe Newswire News

RSS Australian Mining Releases

  • Perseus provides update on Nyanzaga Gold Project
    Perth, May 31, 2024 (GLOBE NEWSWIRE) -- PERSEUS PROGRESSES NYANZAGA GOLD PROJECT Perth, Western Australia/May 31, 2024/Perseus Mining Limited (“Perseus” or the “Company”) (ASX/TSX:PRU) is pleased to provide an update on its recently acquired Nyanzaga Gold Project in Tanzania. HIGHLIGHTS The compulsory acquisition process of the remaining OreCorp shares completed on May 20, 2024 and […]
  • Exploration Results Meyas Sand Gold Project - Sudan
    Perth, May 27, 2024 (GLOBE NEWSWIRE) -- EXPLORATION UPDATE FOR MEYAS SAND GOLD PROJECT - SUDAN Perth, Western Australia/ May 27, 2024/Perseus Mining Limited (ASX/TSX: PRU) is pleased to provide an update on exploration activities and studies completed to date at its Meyas Sands Gold Project (MSGP) in Sudan. The full release with drill results […]
  • Amended & Restated Technical Report to Support Kharmagtai Preliminary Economic Assessment
    TORONTO, May 07, 2024 (GLOBE NEWSWIRE) -- Xanadu Mines Ltd (ASX: XAM, TSX: XAM) (Xanadu, XAM or the Company) announces that the Company has filed an amended and restated independent National Instrument 43-101 technical report titled National Instrument 43-101 Amended and Restated Preliminary Economic Assessment Technical Report, Kharmagtai Copper-Gold Project, South Gobi, Mongolia (PEA), effective […]
  • Perseus Appoints Additional Non-Executive Director
    perth, May 02, 2024 (GLOBE NEWSWIRE) -- perseus mining appoints additional independent non-executive director to its board Perth, Western Australia/May 2, 2024/Perseus Mining Limited (ASX/TSX:PRU) (Perseus or the Company) is pleased to advise that Mr Rick Menell has agreed to join the Board of Perseus in the role of non-executive, independent Director and will take […]
  • Perseus Mining March Quarterly Report
    Perth, April 24, 2024 (GLOBE NEWSWIRE) -- MARCH 2024 QUARTER REPORT Perseus Mining Delivers Another Impressive Quarter PERTH, Western Australia/ April 24, 2024/Perseus Mining Limited (“Perseus” or the “Company”) (TSX & ASX: PRU) reports on its activities for the three months’ period ended March 31, 2024 (the “Quarter”). Key operating indicators and highlights for the […]
  • Compelling Coarse Ore Flotation Results Indicate Throughput Upside for Kharmagtai
    TORONTO, April 23, 2024 (GLOBE NEWSWIRE) -- Xanadu Mines Ltd (ASX: XAM, TSX: XAM) (Xanadu, XAM or the Company) is pleased to provide an update on metallurgical testwork for the Kharmagtai Copper-Gold Project (Kharmagtai) in Mongolia, being developed with the Company’s joint venture partner, Zijin Mining Group Co., Ltd. (Zijin). The Eriez HydroFloat test work […]
  • Bacchus Capital Engaged as Strategic & Project Funding Adviser
    TORONTO, April 18, 2024 (GLOBE NEWSWIRE) -- Xanadu Mines Ltd (ASX: XAM, TSX: XAM) (Xanadu, XAM or the Company) is pleased to announce that it has engaged Bacchus Capital Advisers Limited (Bacchus) as its strategic and project funding adviser in relation to the Kharmagtai Copper-Gold Project in the South Gobi region of Mongolia. Highlights Xanadu […]
  • Silvercorp accepts Perseus's offer for OreCorp
    Perth, April 10, 2024 (GLOBE NEWSWIRE) -- SILVERCORP ACCEPTS THE PERSEUS OFFER FOR ORECORP Perth, Western Australia/April 10, 204/Perseus Mining Limited (ASX/TSX: PRU) (Perseus or PRU) refers to its off-market takeover bid under Chapter 6 of the Australian Corporations Act for all the current and to be issued ordinary shares in OreCorp Limited (ASX: ORR) […]
  • Perseus Mining March Quarter Investor Webinar
    Perth, April 10, 2024 (GLOBE NEWSWIRE) -- QUARTERLY REPORT INVESTOR WEBINAR / CALL Perth, Western Australia/April 10, 2024/Perseus Mining Limited (ASX/TSX: PRU) is hosting an investor webinar and conference call to discuss its March 2024 Quarterly Results, which are anticipated for release around 8:30am AEST on Wednesday April 24, 2024. CALL DETAILS Australia: Wednesday April […]
  • Perseus's Offer for OreCorp Unconditional and Best and Final
    perth, April 08, 2024 (GLOBE NEWSWIRE) -- PERSEUS OFFER UNCONDITIONAL AND BEST AND FINAL Perth, Western Australia/ April 8, 2024/Perseus Mining Limited (ASX/TSX: PRU) (Perseus or PRU) refers to its off-market takeover bid under Chapter 6 of the Australian Corporations Act for all the current and to be issued ordinary shares in OreCorp Limited (ASX: […]

Stay up to date

Get notified about the latest gold mining news as soon as it happens or choose daily or weekly deliveries.
GET Newsletters
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram